Arrayit Microsoft array technology customers at Bio-X Stanford University publish next generation sequencing NGS advance
Arrayit reports $16,900 microarray technology sale to a top immunology research laboratory in the Southwestern USA (link: http://arrayit.com/Services/services.html) arrayit.com/Services/servi…
Arrayit reports $19,000 microarray technology platform sale to a top European lifestyle and wellness testing company
Arrayit reports microarray technology sale to top life science distribution portal Bio-Connect Huissen Netherlands
Arrayit reports Parkinson's Disease Test PDx™ partnering opportunity with top physician in Molecular Medicine India
Arrayit reports microarray technology sale to top life sciences distribution leaders Probiotek located Laredo Mexico
Arrayit reports microarray technology inquiry top scientist Center Optical Materials Clemson University Anderson SC
Arrayit senior management receives speaking invitation at 15th Annual Drug Discovery Congress Nov 9 2017 Xi’an China
?@arrayit? Arrayit reports Parkinson's Disease Test PDx™ partnering opportunity with top physician in Molecular Medicine India (link: http://nimhans.ac.in) nimhans.ac.in
Arrayit reports $400,000 microarray services inquiry from advanced pharmaceutical leader Cellceutix CTIX Beverly MA (link: http://www.cellceutix.com) cellceutix.com
Arrayit reports $168,000 microarray platform sale to leading medical suppliers Medi Laser located in Lahore Pakistan (link: http://www.medilaser.com.pk) medilaser.com.pk
Arrayit Silicon Valley store sales exceed $54 million all-time on 222,269 microarray products and services http:// shop.arrayit.com
Arrayit receives new financing lead that could generate 6,000 x $100K = $600MM in Arrayit microarray platform sales http:// arrayit.com
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Check out their Facebook page: Arrayit Corporation
Follow $ARYC on Twitter @Arrayit
Avant Diagnostics, Inc. provide the market’s first large panel biomarker monitoring test for ovarian cancer (OVC). OvaDx® is advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.